ArticleJCO oncology practice2025
Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer.
Article in JCO oncology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessing Financial Toxicity in Cancer: A Global Systematic Review and Meta-Analysis Using an Asset Framework.Cancer medicine · 2026Pooled it
- Effect of early integration of supportive care in addition to standard care in patients with breast cancer: A randomised controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Trial
- Exploring the Dynamics of Perioperative Quality of Life in Patients with Pancreatic Cancer: A Cross-Lagged Panel Network Analysis.Annals of surgical oncology · 2026Article
- Understanding financial toxicity in cancer care through a social-ecological lens.Current opinion in oncology · 2026Review
- Barriers to continuity of outpatient infusion-port maintenance among patients with cancer: a single-center cross-sectional study in China.Frontiers in public health · 2026Observational
- Financial toxicity in pediatric cancer: lived experiences and coping strategies of parents.BMC health services research · 2025Article
- Screened but Still Struggling: Challenges in Delivering Financial Assistance After Positive Financial Toxicity Screens.JCO oncology practice · 2025Article
- The Financial Toxicity of Hepatopancreatobiliary Cancer: An Analysis of the 1997-2023 National Health Interview Survey.Journal of gastrointestinal cancer · 2025Article
- Review
- Cost-effectiveness of open versus laparoscopic pancreaticoduodenectomy: a retrospective Markov model analysis from China.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeFinancial toxicity (FT) is increasingly recognized as a major issue in cancer care. We evaluated the prevalence and risk factors for FT in patients with pancreatic ductal adenocarcinoma (PDAC) and FT associations with treatment adherence and quality of life (QOL).
methodsA screening questionnaire based on the Comprehensive Score for Financial Toxicity (COST) was implemented at our National Cancer Institute-designated comprehensive cancer center. Respondents with pathologic diagnosis of PDAC who completed >50% of prompts between June 2022 and June 2023 were analyzed. COST ≤16 was categorized as FT. Associations between FT and demographic and clinical factors were assessed using logistic regression, and QOL was assessed using linear regression.
resultsOf the 1,888 patients with PDAC, 1,162 completed the COST questionnaire, and 1,079 met the inclusion criteria. The prevalence of FT was 23% (n = 245); 37% of patients with FT reported medication nonadherence due to cost. Demographic factors and poor performance status were associated with FT. Treatment-naïve patients were more likely to report FT compared with those on induction, adjuvant, or palliative therapy (
conclusionFT affected nearly one in four patients with PDAC at a high-volume cancer center and was associated with worse QOL and medication nonadherence. Universal screening and interventions to reduce FT are warranted. Clinical trials investigating QOL as an end point must account for potential confounding due to FT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.